Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7NA4

HDM2 in complex with compound 63

Summary for 7NA4
Entry DOI10.2210/pdb7na4/pdb
DescriptorIsoform 11 of E3 ubiquitin-protein ligase Mdm2, 3-[4-(5-chloropyridin-3-yl)-2-[(R)-cyclopropyl(ethoxy)methyl]-3-{(1R)-1-[(1r,4R)-4-methylcyclohexyl]ethyl}-3H-imidazo[4,5-c]pyridin-6-yl]-1,2,4-oxadiazol-5(4H)-one, GLYCEROL, ... (5 entities in total)
Functional Keywordsp53, drug design, protein-protein interactions, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight13349.09
Authors
Scapin, G. (deposition date: 2021-06-19, release date: 2021-11-10, Last modification date: 2024-05-22)
Primary citationReutershan, M.H.,Machacek, M.R.,Altman, M.D.,Bogen, S.,Cai, M.,Cammarano, C.,Chen, D.,Christopher, M.,Cryan, J.,Daublain, P.,Fradera, X.,Geda, P.,Goldenblatt, P.,Hill, A.D.,Kemper, R.A.,Kutilek, V.,Li, C.,Martinez, M.,McCoy, M.,Nair, L.,Pan, W.,Thompson, C.F.,Scapin, G.,Shizuka, M.,Spatz, M.L.,Steinhuebel, D.,Sun, B.,Voss, M.E.,Wang, X.,Yang, L.,Yeh, T.C.,Dussault, I.,Marshall, C.G.,Trotter, B.W.
Discovery of MK-4688 : an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.
J.Med.Chem., 64:16213-16241, 2021
Cited by
PubMed Abstract: Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward this goal. Adding to recent success in this area, we describe herein our efforts to optimize a novel purine carboxylic acid-derived inhibitor of the HDM2-p53 PPI into a series of low-projected dose inhibitors with overall favorable pharmacokinetic and physical properties. Ultimately, a strategy focused on leveraging known binding hot spots coupled with biostructural information to guide the design of conformationally constrained analogs and a focus on efficiency metrics led to the discovery of (compound ), a highly potent, selective, and low-molecular-weight inhibitor suitable for clinical investigation.
PubMed: 34714078
DOI: 10.1021/acs.jmedchem.1c01524
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.84 Å)
Structure validation

229380

PDB entries from 2024-12-25

PDB statisticsPDBj update infoContact PDBjnumon